Bioterrorism in Medical Technology

Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program

... the tests for VHFs, some of which are potential bioterrorism agents due to their high fatality rate and ease ... the world, but will also fill a critical gap in bioterrorism defense. Now, under the new NIH award, we will ... are of concern to the public health and bioterrorism preparedness communities. About Corgenix ...

Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains

... start a Phase III trial by the end of 2008. One Vaccine to Combat Four bioterrorism Agents U.S. Army researchers will also report success in mouse ... botulism, plague and staphylococcus -- all of which might be used as bioterrorism agents. The vaccine, developed by the U.S. Army Research Institute ...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

... developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the ...

Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study

... all of our studies show that treatment with Anthim has the potential to provide significant therapeutic benefit for people infected with anthrax in a bioterrorism emergency." Currently antibiotics represent the only therapeutic option for anthrax infection. Antibiotics target the bacteria, but can still fail ...

DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation

... developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the ...

AlphaVax Continues to Expand the Use of Its Vaccine Platform

... NIAID grant to date is an excellent demonstration of the potential of our alphavirus vector platform to address many different diseases as well as bioterrorism threats. We have shown efficacy of this platform in numerous animal models and safety and immunogenicity in three clinical trials to date. We look ...

New York Infection Prevention Expert Named Recipient of Carole DeMille Award

... including chair of the TB Task Force and as a member of the Practice Guidance Council, Public Policy Committee, Mandatory Reporting Task Force and bioterrorism Task Force. She is currently an external advisor to the Public Policy Committee. She also serves as a liaison representative to the CDC's Advisory ...

Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

... of CAP caused by Haemophilus influenzae. The following poster presentations demonstrated the potency of cethromycin as a potential treatment against bioterrorism pathogens: "Efficacy of Cethromycin Against a Lethal Inhalation Anthrax Challenge in Rhesus Macaques" All antibiotic treated animals maintained ...

Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

... of CAP caused by Haemophilus influenzae. The following poster presentations demonstrated the potency of cethromycin as a potential treatment against bioterrorism pathogens: "Efficacy of Cethromycin Against a Lethal Inhalation Anthrax Challenge in Rhesus Macaques" All antibiotic treated animals maintained ...

Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

... and Management Tuesday, September 18, 11:15 a.m. Central Daylight Time, Room E253D Poster Session 222: Pathogenesis and Therapeutics in Agents of bioterrorism -- Poster: Poster B-2031: Efficacy of Cethromycin Against a Lethal Inhalation Anthrax Challenge in Rhesus Macaques Wednesday, September 19, ...

ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells

... of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(R), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera(TM) is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of ...

ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.

... of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(R), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of ...

DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC

... PhD, Professor of Medicine and Director of the Center for Research on bioterrorism and Biodefense at Jefferson Medical College. "First, they are a clear ... and serious gastrointestinal ("GI") diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec® (oral beclomethasone dipropionate), ...

IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation

... of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(TM), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of ...

ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent

... of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(TM), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from modified Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect ...

IR BioSciences Announces Promising Data from Study of Its Compound Homspera

... of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(TM), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from modified Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect ...

DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC

... to treat life-threatening side effects of cancer treatments and serious gastrointestinal ("GI") diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid being developed for the ...